Fexofenadine: A review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria

Drugs

Volumn 59, Issue 2, 2000, Pages 301-321

  Simpson, Kerryn ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CETIRIZINE; CHLORPHENIRAMINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DESLORATADINE; DIPHENHYDRAMINE; DOXEPIN; EBASTINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HYDROXYZINE; IPRATROPIUM BROMIDE; KETOCONAZOLE; LORATADINE; MONTELUKAST; NORASTEMIZOLE; PREDNISOLONE; PREDNISONE; PROMETHAZINE; PSEUDOEPHEDRINE; TERFENADINE; TROGLITAZONE;

ALLERGIC RHINITIS; ANTIINFLAMMATORY ACTIVITY; CHRONIC URTICARIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SCREENING; DRUG TOLERABILITY; EXPERIMENTAL MODEL; HEADACHE; HUMAN; IDIOPATHIC DISEASE; NAUSEA; NONHUMAN; QUALITY OF LIFE; RASH; REVIEW; SKIN IRRITATION;

EID: 0034028814     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059020-00020     Document Type: Review

References (78)

1. 1. Howarth PH. ABC of allergies: pathogenic mechanisms: a rational basis for treatment. BMJ 1998 Mar 7; 316: 758-61
2. 2. Hadley JA. Evaluation and management of allergic rhinitis. Med Clin North Am 1999; 83 (1): 13-25
3. 3. Tharp MD. Chronic urticaria: pathophysiology and treatment approaches. J Allergy Clin Immunol 1996 Dec; 98: 325-30
4. 4. Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 1998 Nov; 51 (Pt 2): 478-518
5. 5. The impact of allergic rhinitis on quality of life and other airway diseases: summary of a European conference. Allergy 1998; 53 (41 Suppl.): 3-30
6. 6. O'Donnell BF, Lawlor F. Chronic urticaria: practical recommendations for management. Clin Immunother 1996 Nov; 6: 341-51
7. 7. Kennedy MS. Evaluation of chronic eczema and urticaria and angioedema. Immunol Allergy Clin North Am 1999; 19 (1): 19-33
8. 8. Kwong KY, Maalouf N, Jones CA. Urticaria and angioedema: pathophysiology, diagnosis, and treatment. Pediatr Ann 1998; 27 (11): 719-24
9. 9. Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamines. Expert Opin Invest Drug 1998 Jul; 7: 1045-54
10. 10. Markham A, Wagstaff AJ. Fexofenadine. Drugs 1998 Feb; 55: 269-74
11. 11. Hey JA, del Prado M, Sherwood J, et al. Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects [see comments]. Arzneimittelforschung 1996 Feb; 46: 153-8
12. 12. Hoechst Marion Roussel. Fexofenadine prescribing information 1999. Kansas City, Missouri, USA
13. 13. Grant JA, Danielson L, Rihoux J-P, et al. A comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo in suppressing the cutaneous response to histamine. Int Arch Allergy Immunol 1999; 118: 339-40
14. 14. Simons FER, Simons KJ. Clinical pharmacology of new histamine HI receptor antagonists. Clin Pharmacokinet 1999 May; 36: 329-52
15. 15. Monroe EW, Daly AF, Shalhoub RF. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 1997 Feb; 99: S798-806
16. 16. Simons FER, Simons KJ. Peripheral HI-blockade effect of fexofenadine. Ann Allergy Asthma Immunol 1997 Dec; 79: 530-2
17. 17. Balcer SL, Baker TW, Bugos CL, et al. Comparison of fexofenadine (F), terfenadine (T), loratadine (L) and placebo (P) in a double-blind crossover trial utilizing a skin test model to examine suppression of histamine-induced wheal and flare [abstract]. J Allergy Clin Immunol 1998 Jan; 101 (Pt 2): S243
18. 18. Russell T, Burgess R, Donahue R, et al. A comparison of peripheral HI blockade between single doses of fexofenadine HCl and terfenadine. Allergy 1999; 54 Suppl. 52: 156
19. 19. Harris AG, Iezzoni DG, Hubbell JP. Comparative pharmacokinetic and pharmacodynamic crossover study of Seldane tablets and Allegra capsules [abstract]. J Allergy Clin Immunol 1999 Jan; 103 (Pt 2): S253
20. 20. Ballmer-Weber BK, Wüthrich B. Inhibition of histamine or allergen induced wheals by a single dose of cetirizine or fexofenadine [abstract]. Allergy 1998; 53 Suppl. 43: 78
21. 21. Paolieri F, Battifora M, Riccio AM, et al. Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines. Ann Allergy Asthma Immunol 1998; 81 (6): 601-7
22. 22. Ciprandi G, Passalacqua G, Caononica GW. Effects of HI antihistamine on adhesion molecules: a possible rational for long-term treatment. Clin Exp Allergy 1999; 29 (3): 49-53
23. 23. Halliday DJ, Briscoe MP, Welsh A, et al. Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit. Ann Allergy Asthma Immunol 1997 Dec; 79: 533-40
24. 24. Terrien M-H, Rahm F, Fellrath J-M, et al. Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen. J Allergy Clin Immunol 1999 Jun; 103: 1025-30
25. 25. Simons FER, Johnston L, Gu X, et al. Suppression of the early and late cutaneous allergic responses using the HI-receptor antagonist fexofenadine and the cysteinyl leukotrienel-antagonist montelukast. J Allergy Clin Immunol 2000. In press
26. 26. Hey JA, Kreutner W, Danzig M, et al. Comparative effects of antihistamines in an experimental model of QTc prolongation and on ventricular K+ currents [abstract]. Allergy 1997; 52 (37) Suppl.: 208
27. 27. Pratt C, Brown AM, Rampe D, et al. Cardiovascular safety of fexofendaine HCl. Clin Exp Allergy 1999; 29 Suppl. 3: 212-6
28. 28. Viskin S. Long QT intervals and torsade de pointes. Lancet 1999; 354 (9190): 1625-33
29. 29. Rampe D, Wible B, Brown AM, et al. Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart. Mol Pharmacol 1993; 44: 1240-5
30. 30. Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 26: 1532-6
31. 31. Pratt CM, Mason J, Russell T, et al. Cardiovascular safety of fexofenadine HCl. Am J Cardiol 1999 May 15; 83: 1451-4
32. 32. Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of fexofenadine HCl in healthy, male volunteers. Hoechst Marion Roussel (Data on file)
33. 33. Russell T, Stoltz M, Weir S. Pharmacokinetics, pharmacodynamics, and tolerance of single-and multiple-dose fexofenadine hydrochloride in healthy male volunteers. Clin Pharmacol Ther 1998 Dec; 64: 612-21
34. 34. Robbins DK, Castles MA, Pack DJ, et al. Dose proportionality and comparison of single and multiple dose pharmacokinetics of fexofenadine (MDL 16455) and its enantiomers in healthy male volunteers. Biopharm Drug Dispos 1998; 19 (7): 455-63
35. 35. Stoltz M, Arumugham T, Lippert C, et al. Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A). Biopharm Drug Dispos 1997 Oct; 18: 645-8
36. 36. Lippert CL, Rao N, Eller M, et al. Pharmacokinetics of fexofenadine in liver diseased patients. Pharm Res 1996; 13 (9 Suppl.): S431
37. 37. Rao N, Weilert DR, Grace MGA, et al. Pharmacokinetics of terfenadine-acid-metabolite, MDL 16,455, in healthy geriatric subjects [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S386
38. 38. Simons FE, Bergman JN, Watson WT, et al. The clinical pharmacology of fexofenadine in children. J Allergy Clin Immunol 1996 Dec; 98 (6 Pt 1): 1062-4
39. 39. Russell T, Arumugham T, Eller M, et al. A comparison of MDL 16,455A pharmacokinetics by gender [abstract]. Pharm Res 1995 Sep; 12 Suppl.: S389
40. 40. Loi CM, Koup JR, Vassos AB, et al. Effect of troglitazone on fexofenadine pharmacokinetics [abstract]. Clin Pharmacol Ther 1999 Feb; 65: 186
41. 41. Kaiser H, Harris AG, Capano D, et al. A double-blind, placebo-controlled comparison of the safety and efficacy of loratadine (Claritin), fexofenadine HCl (Allegra), and placebo in the treatment of subjects with seasonal allergic rhinitis (SAR) [abstract]. Allergy 1999; 54 Suppl. 52: 155
42. 42. Prenner B, Capano D, Harris AG. The safety and efficacy of loratadine (Claritin) versus fexofenadine HCl (Allegra) in the treatment of seasonal allergic rhinitis (SAR): a multicenter crossover comparison with treatment of nonresponders [abstract]. Allergy 1999; 54 Suppl. 52
43. 43. van Cauwenberge P, Juniper EF, Meltzer E, et al. Efficacy, safety and quality of life - a comparison between fexofenadine, loratadine, and placebo in the treatment of seasonal allergic rhinitis. Presented at the American College of Allergy, Asthma and Immunology Conference, 1999 Nov; Chicago
44. 44. Bernstein DI, Schoenwetter WF, Nathan RA, et al. Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997 Nov; 79: 443-8
45. 45. Bronsky EA, Falliers CJ, Kaiser HB, et al. Effectiveness and safety of fexofenadine, a new nonsedating HI-receptor antagonist, in the treatment of Fall allergies. Allergy Asthma Proc 1998 May-Jun; 19: 135-41
46. 46. Casale TB, Andrade C, Qu R. Safety and efficacy of once-daily fexofenadine HCl in the treatment of Autumn seasonal allergic rhinitis. Allergy Asthma Proc 1999 May-Jun; 20: 193-8
47. 47. Sussman GL, Mason J, Compton D, et al. The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis. J Allergy Clin Immunol 1999 Jul; 104: 100-6
48. 48. Howarth PH, Stern MA, Roi L, et al. Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis. J Allergy Clin Immunol 1999; 104 (5): 927-33
49. 49. van Cauwenberge P, Juniper EF, Dumas C, et al. Efficacy, safety and quality of life - a comparison between fexofenadine, loratadine, and placebo in the treatment of seasonal allergic rhinitis. Ann Allergy Clin Immunol 2000 Feb. In press
50. 50. Cleary MI, Clouse JC, Roht LH, et al. Prescribing patterns of non-sedating antihistamines and daily dose differences in a managed care population [abstract no. 71]. Presented at the American College of Asthma, Allergy and Immunology Conference, 1999 Nov; Chicago
51. 51. Finn AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999; 104 (5): 1071-8
52. 52. Paul E, Berth-Jones K, Ortonne J-P, et al. Fexofenadine hydrochloride in the treatment of chronic idiopathic urticaria: a placebo-controlled, parallel-group, dose-ranging study. J Dermatol Treat 1998 Sep; 9: 143-9
53. 53. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83
54. 54. Reilly MC, Tanner A, Meltzer EO. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest 1996; 11 (5): 278-88
55. 55. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmaco Economics 1993; 4 (5): 353-65
56. 56. Zimmerman LS, De Anda CS, McKenzie DR, et al. Clinical experience with the mini-rhinoconjunctivitis quality of life questionnaire (Mini-RQLQ) in seasonal allergic rhinitis (SAR) patients receiving fexofenadine [abstract]. J Allergy Clin Immunol 1999 Jan; 103 (Pt 2): S251
57. 57. Meltzer EO, Casale TB, Nathan RA, et al. Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1999 Jan; 83: 311-7
58. 58. Tanner LA, Reilly M, Meltzer EO, el al. Effect of fexofenadine HCl on quality of life and work, classroom, and daily activity impairment in patients with seasonal allergic rhinitis. Am J Managed Care 1999; 5 (4 Suppl.): S235-47
59. 59. Thompson A, Finn A, Schoenwetter W. Effect of 60 mg BID fexofenadine HCl on quality of life, work productivity, and regular activity in patients with chronic idiopathic urticaria [abstract]. Ann Allergy Asthma Immunol 1999 Jan; 82: 122
60. 60. Long J, Meltzer EO, Scott-Dawdy K, et al. Safety of fexofenadine HCl in children treated for seasonal allergic rhinitis [abstract]. J Allergy Clin Immunol 1999 Jan; 103 (Pt 2): S254
61. 61. Mason J, Reynolds R, Rao N. The systemic safety of fexofenadine. Clin Exp Allergy 1999; 29 Suppl. 3: 163-70
62. 62. Craig-McFeely PM, Freemantle SL, Pearce GL, et al. Experience of fexofenadine and cardiac side effects in general practice use in England. Pharmacoepidemiol Drug Saf 1999; 8 Suppl. 2: S108
63. 63. Nathan RA, Mason J, Bernstein DI, et al. Long-term tolerability of fexofenadine in healthy volunteers. Clin Drug Invest 1999; 18 (4): 317-28
64. 64. Rankin AC. Non-sedating antihistamines and cardiac arrhythmia. Lancet 1997; 350 (9085): 1115-6
65. 65. Nsouli SM. Electrocardiographic effects (ECG) of fexofenadine (FF) in allergic rhinitis patients [abstract]. Ann Allergy Asthma Immunol 1998 Jan; 80: 109
66. 66. Pinto YM, van Gelder IC, Heeringa M, et al. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999 Mar 20; 353: 980
67. 67. Ledford DK, Lockey RF. Allergic rhinitis: Offering relief this season. J-Respir-Dis 1998; 19 (8): 647-66
68. 68. Shamsi Z, Kimber S, Hindmarch I. An investigation into the effects of cetirizine and loratadine on cognitive function and psychomotor performance. Eur Neuropsychopharmacol 1999; 9 Suppl. 5: 369-70
69. 69. Nicholson AN, Stone BM, Turner C, et al. Antihistamines and aircrews: usefulness of fexofenadine. Aviat Space Environ Med 2000. In press
70. 70. Vermeeren A, O'Hanlon JF. Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998 Mar; 101: 306-11
71. 71. Hindmarch I, Shamsi Z, Stanley N, et al. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999 Aug; 48: 200-6
72. 72. Weiler JM, Bloomfield JR, Layton TA, et al. Effects of fexofenadine, diphenhydramine and alcohol on driving performance in the Iowa Driving Simulator (IDS) [abstract]. Ann Allergy Asthma Immunol 1999 Jan; 82: 112
73. 73. Fexofenadine hydrochloride. AHFS Drug Information, 1999
74. 74. Telfast* 120 & 180. ABPI compendium of data sheets and summaries of product characteristics 1999. Datapharm Publications Ltd., London
75. 75. Meltzer EO. Treatment options for the child with allergic rhinitis. Clin Pediatr 1998; 37 (1): 1-10
76. 76. Bousquet J, Lockey R, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998; 53 (44 Suppl.): 4-42
77. 77. Kozma CM, Sadik MK, Watrous ML. Economic outcomes for the treatment of allergic rhinitis. Pharmacoeconomics 1996 Jul; 10: 4-13
78. 78. LaForce C. Use of nasal steroids in managing allergic rhinitis. J Allergy Clin Immunol 1999 Mar; 103 (Pt 2) Suppl.: S388-394